- About
-
Services
-
Offerings
- Offerings
- ADME and Bioanalytical Sciences
- Analytical Chemistry
- Assay Development
- Biochemical Assays
- Biophysical Assays
- Cell Based Assays
- Computational Chemistry
- Fragment and Compound Screening
- Integrated Drug Discovery Services
- Medicinal Chemistry
- Protein Expression and Purification Services
- Structural Biology
- Synthetic Chemistry
- Virtual screening
-
Research Phases
- Research Phases
- Hit Identification
- Hit to Lead
- Lead Optimisation
- Therapeutic Areas
- Target Classes
-
Approaches & Techniques
- Approaches & Techniques
- CDH (Target Gene Fragmentation)
- Cryogenic Electron Microscopy (Cryo-EM)
- Differential Scanning Fluorimetry (DSF) and nanoDSF Services
- Direct-to-Biology (D2B)
- eProtein Discovery
- Flow Cytometry
- Fragment Based Drug Discovery (FBDD)
- FragmentBuilder
- Grating-Coupled Interferometry
- High Throughput Screening
- Isothermal Titration Calorimetry (ITC)
- LeadBuilder
- PoLiPa (Membrane Protein Solubilisation)
- Spectral Shift and MST Services
- Structure Based Drug Design (SBDD)
- Surface Plasmon Resonance (SPR)
- X-ray Crystallography
-
Offerings
- Library
- News & Events
- Careers
Join our webinar series discussing the latest developments in drug discovery. Register now.
Enquire
BioJapan 2015
Pacifico Yokohama, Japan
Tuesday, 13 Oct '15
BioJapan exists to facilitate cooperation between Japanese and international biotech companies. At this year’s event in Yokohama, Domainex CEO Eddy Littler will be speaking to a gathering of the industry’s top scientific and business minds on the anti-inflammatory TBK1 & IKKε inhibitors developed by Domainex in a seminar titled ‘IKK epsilon inhibitors with activity in inflammatory disease: COPD, psoriasis and Lupus’.
http://www.ics-expo.jp/biojapan/
News
Start your next project with Domainex
Contact one of our experts today